A Multicentric, Retrospective Efficacy and Safety Study of Nanosomal Docetaxel Lipid Suspension in Metastatic Castration-Resistant Prostate Cancer
Joint Authors
Samar, Aseem
Tiwari, Srikant
Subramanian, Sundaram
Joshi, Nisarg
Sejpal, Jaykumar
Khan, Mujtaba A.
Ahmad, Imran
Source
Issue
Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-7, 7 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2020-12-16
Country of Publication
Egypt
No. of Pages
7
Main Subjects
Abstract EN
Purpose.
To evaluate the efficacy and safety of nanosomal docetaxel lipid suspension (NDLS, DoceAqualip) in patients with metastatic castration-resistant prostate cancer (mCRPC).
Materials and Methods.
In this multicenter, retrospective study, we analyzed the medical charts of mCRPC patients, who were treated with NDLS administered as 2-weekly (50 mg/m2) or 3-weekly regimens (75 mg/m2).
The study endpoints were prostate-specific antigen (PSA) response (>50% PSA decline from baseline), PSA progression (PSA increase from baseline beyond 12 weeks: ≥25% and ≥2 ng/mL), median PSA decline, and time-to-treatment failure (TTF).
Overall survival (OS) and safety were also evaluated.
Results.
Data of 24 patients with mCRPC were analyzed in this study.
NDLS was administered as a 2-weekly regimen in 37.5% (9/24; all first-line) patients and as a 3-weekly regimen in 62.5% patients (15/24; first-line: 20% (3/15), second-line: 80% (12/15)).
Overall, PSA response was reported in 66.7% (16/24) patients.
The PSA response was 77.8% (7/9 patients) in the 2-weekly group and 60% (9/15 patients) in the 3-weekly group.
The median decline in PSA was 96.31% in the 2-weekly group and 83.29% in the 3-weekly group; the median TTF was 6.7 and 6.5 months in the 2 weekly group and 3-weekly group, respectively.
The median OS was 14.6 months (follow-up: 5.5–25.8 months) in the 2-weekly group whereas it was not reached in the 3-weekly group (follow-up: 7.9–15.6 months).
The most common hematological AEs were anemia, lymphopenia, thrombocytopenia, and neutropenia whereas nausea, weakness, constipation, vomiting, and diarrhea were the most common (≥10%) nonhematological AEs.
Overall, NDLS treatment was well tolerated without any new safety concerns.
Conclusions.
Nanosomal docetaxel lipid suspension (2-weekly or 3-weekly) was effective and well tolerated in patients with metastatic castration-resistant prostate cancer.
American Psychological Association (APA)
Samar, Aseem& Tiwari, Srikant& Subramanian, Sundaram& Joshi, Nisarg& Sejpal, Jaykumar& Khan, Mujtaba A.…[et al.]. 2020. A Multicentric, Retrospective Efficacy and Safety Study of Nanosomal Docetaxel Lipid Suspension in Metastatic Castration-Resistant Prostate Cancer. Prostate Cancer،Vol. 2020, no. 2020, pp.1-7.
https://search.emarefa.net/detail/BIM-1206329
Modern Language Association (MLA)
Samar, Aseem…[et al.]. A Multicentric, Retrospective Efficacy and Safety Study of Nanosomal Docetaxel Lipid Suspension in Metastatic Castration-Resistant Prostate Cancer. Prostate Cancer No. 2020 (2020), pp.1-7.
https://search.emarefa.net/detail/BIM-1206329
American Medical Association (AMA)
Samar, Aseem& Tiwari, Srikant& Subramanian, Sundaram& Joshi, Nisarg& Sejpal, Jaykumar& Khan, Mujtaba A.…[et al.]. A Multicentric, Retrospective Efficacy and Safety Study of Nanosomal Docetaxel Lipid Suspension in Metastatic Castration-Resistant Prostate Cancer. Prostate Cancer. 2020. Vol. 2020, no. 2020, pp.1-7.
https://search.emarefa.net/detail/BIM-1206329
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1206329